Overview Intravenous infusion of umbilical cord blood cells is a therapeutic procedure used in patients recovering from a stroke. The umbilical cord blood is taken from the placenta via the umbilical cord.
To achieve an optimal therapeutic effect, a dose of 50 million cells per kg is required, and each infusion includes umbilical cord blood from 4 to 8 donors. The entire infusion series extends from two to three days, and after each infusion, the patient is monitored for possible adverse reactions for several hours. In the majority of patients, umbilical cord blood infusions have improved cognitive and motor functions. These functional improvements are noticeable within the first weeks after infusion. Adverse reactions to cord blood infusions are rare and generally mild.
The treatment effect The umbilical cord blood infusion is not intended as a substitute for standard therapy in the treatment of strokes, but as an additional therapeutic approach that can lead to a further improvement in cognitive and motor functions. In patients undergoing cord blood therapy, there is no need to temporarily discontinue other types of drug or physical therapy. Intravenous cord blood infusions improve the rain fraction activity of brain cells in stroke patients. Clinical studies suggest that cord blood therapy is more effective when administered shortly after stroke.